Abstract
dc:description.abstractIn FXS, FMR1 gene silencing leads to multiple symptoms including intellectual disability, hypersensitivity to sensory stimuli, epilepsy and autism. Re-expression of FMR1 through gene therapy could be a promising therapeutic approach, however many questions remain about the viability of this strategy. Previous work investigating viral re-expression of FMR1 in Fmr1⁻/ʸ mice and rats have shown mixed results regarding behavioural rescue. This may be due to differences in FMRP re-expression levels in underlying circuits, however the specific cell types that underlie many Fmr1⁻/ʸ phenotypes are not known. This makes it difficult to address important questions regarding the efficacy of gene therapy including: How much FMRP is needed per cell? How long must FMRP be re-expressed? And, what is the maximum age FMRP re-expression can be therapeutically useful? We took advantage of recent work showing that Fmr1 re-expression in neurons in inferior colliculus (IC) is sufficient to prevent audiogenic seizures (AGS) in the Fmr1⁻/ʸ mouse, allowing us to link cellular expression levels of FMRP directly to level of hyperactivation and seizure expression (Gonzalez et al, 2019; Louros et al, 2023). In this thesis an AAV9-hFMR1 gene therapy approach is used to test the impact of FMRP re-expression in Fmr1⁻/ʸ brain, both when introduced at an early neonatal timepoint or when re-expressed for 1 week in IC in adult mice. Additionally, different techniques were performed to address the underlying mechanism of FMRP re-expression (ie, the vglut2 neurons versus other neuronal type), and TRAP-seq was used to identify molecular pathways involved in seizures phenotype. Our results show that intracerebroventricular injection of AAV9-hFMR1 at P0-2 leads to a robust 2-fold re-expression of FMRP throughout the brain at 8 weeks, which is sufficient to prevent AGS. Additional testing reveals a similar 2-fold re-expression of FMRP at 3 weeks, and quantification of cFos neurons in the IC shows that FMRP reexpression prevents the hyperactivation that occurs upon sound stimulation before the onset of seizures. This 3-week expression is sufficient to prevent AGS in the Fmr1⁻/ʸ mouse. Importantly, we further find that stereotaxic injection of AAV9-hFMR1 into the IC of adult Fmr1⁻/ʸ mice prevents AGS after only 1 week of expression. These results show that AAV9-hFMR1 administration in either neonates or adults leads to a therapeutically viable re-expression of FMRP that prevents hyperactivity and seizures in the Fmr1⁻/ʸ mouse within 1 week. These findings hold promise for gene therapy in FXS.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Maio, Beatriz
- Advisors dc:contributor.advisor
-
- Kind, Peter
- Cobb, Stuart
- Osterweil, Emily
Subjects
dc:subject × 8Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/5371